NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

腦腫瘤診斷和治療的全球市場:按類型(診斷,治療)的市場研究,預測(∼2025年),COVID-19的累積影響

Brain Tumor Diagnosis & Therapeutics Market Research Report by Type (Diagnosis and Therapeutics), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 1001136
出版日期 內容資訊 英文 199 Pages
商品交期: 最快1-2個工作天內
價格
腦腫瘤診斷和治療的全球市場:按類型(診斷,治療)的市場研究,預測(∼2025年),COVID-19的累積影響 Brain Tumor Diagnosis & Therapeutics Market Research Report by Type (Diagnosis and Therapeutics), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 199 Pages
簡介

全球腦腫瘤診斷和治療市場預計將從2020年的1,260.91百萬美元增長到2025年底的1,882,273美元。

市場細分和覆蓋率

該研究報告對腦腫瘤診斷和治療的全球市場進行了分類,預測了收入,並分析了以下每個子市場的趨勢:

  • 按類型,已經對診斷和治療方法的市場進行了調查。在腦血管造影,CT掃瞄,EEG,腰椎穿刺,分子檢查,MRI,PET-CT掃瞄和組織採樣中進一步研究了診斷部分。在化學療法,免疫療法,放射療法,手術和靶向療法之間進一步研究了治療方案。
  • 按地區,對美洲,亞太地區以及歐洲和中東/非洲的市場進行了調查。美洲是阿根廷,巴西,加拿大,墨西哥和美國。亞太地區是澳大利亞,中國,印度,印度尼西亞,日本,馬來西亞,菲律賓,韓國和泰國。在法國,德國,意大利,荷蘭,卡塔爾,俄羅斯,沙特阿拉伯,南非,西班牙,阿拉伯聯合酋長國和英國對歐洲以及中東和非洲地區進行了調查。 2020年,美洲是腦腫瘤診斷和治療市場中最大的市場。同時,預計亞太地區將在預測期內以最快的複合年增長率增長。

企業可用性簡介

本報告來自Amgen Inc.、AstraZeneca PLC、Bayer AG、Bristol-Myers Squibb Co、Carestream Health, Inc.、Eisai Inc.、F. Hoffmann-La Roche Ltd、Fujifilm Corporation、GE Healthcare Inc.、GlaxoSmithKline PLC、Hitachi, Ltd.、Johnson & Johnson、Merck & Co. Inc.、Novartis AG、Pfizer, Inc.、Philips Healthcare、S&P Global Inc.、Shimadzu Corporation、Siemens Healthineers AG、Toshiba Corporation、Toshiba Medical Systems等。我們正在深入探索主要供應商在最近的重大發展和創新概況。

COVID-19的累積影響

預計COVID-19將在預測期內對行業增長產生長期影響,因為這是無與倫比的全球公共衛生突發事件,幾乎影響了每個行業。我們正在進行的研究擴大了研究框架,以確保它包括潛在的COVID-19問題和潛在的未來路徑。該調查提供了對COVID-19的見解,並考慮了消費者行為和需求,購買模式,供應鏈改路,當前市場勢力動態以及政府的主要干預措施的變化。更新後的調查提供了見解,分析,估計和預測,其中考慮了COVID-19對市場的影響。

該報告按類型和地區對全球腦腫瘤診斷和治療市場,市場概況,市場增長和抑制因素進行分析,市場機會,COVID-19的影響進行了調查,並提供了系統的信息,例如市場規模趨勢和預測,競爭狀況以及主要公司的概況。

360iResearch(TM)FPNV定位矩陣

360iResearch(TM)FPNV定位矩陣提供業務戰略(業務增長,行業覆蓋範圍,財務可行性,渠道支持),以幫助公司做出更好的決策並瞭解其競爭格局,並根據產品滿意度對市場中的供應商進行評估和分類(性價比,易用性,產品功能和客戶支持)。

360iResearch(TM)競爭戰略窗口:

360iResearch(TM)競爭戰略窗口從市場,應用和區域角度分析競爭條件。這有助於供應商定義能力和機會之間的協調或適應,以實現未來的增長前景。在預測期內,供應商將採用持續的併購策略,區域擴展,研發和新產品實施策略,以最佳或有利地適應進一步的業務擴展和增長。

目錄

第1章簡介

  • 調查目的
  • 市場細分和覆蓋範圍
  • 考慮調查的年份
  • 貨幣和價格
  • 語言
  • 限制
  • 利益相關者

第2章調查方法

  • 調查過程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:測量設備
    • 集合:數據源
    • 分析:數據解釋
    • 公式:數據驗證
    • 已發佈:調查報告
    • 重複:報告更新
  • 進行調查
    • 開始:調查過程
    • 計劃:創建調查計劃
    • 執行:進行調查
    • 驗證:發現和分析
    • 出版物:調查報告
  • 調查結果

第3章執行摘要

  • 市場展望
  • 種類展望
  • 區域展望
  • 競爭對手展望

第4章市場概述

  • COVID-19的累積效果

第5章市場洞察

  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
    • 挑戰
  • 波特五力分析
    • 新進入者的威脅
    • 替代威脅
    • 客戶的議價能力
    • 供應商的談判能力
    • 行業競爭

第6章按類型

  • 診斷
    • 腦動脈造影
    • CT掃瞄
    • 腦電圖
    • 腰穿
    • 分子測試
    • 核磁共振
    • PET-CT掃瞄
    • 組織採樣
  • 治療
    • 化學療法
    • 免疫療法
    • 放射治療
    • 手術
    • 目標療法

第7章美洲

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第8章亞太地區

  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第9章歐洲,中東/非洲

  • 法國
  • 德國
  • 意大利
  • 荷蘭
  • 卡塔爾
  • 俄羅斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合酋長國
  • 英國

第10章競爭情況

  • FPNV定位矩陣
    • 象限
    • 經營策略
    • 產品滿意度
  • 市場排名分析
  • 市場份額分析
  • 競爭性SWOT分析
  • 競爭情景
    • 併購
    • 協議,合作和夥伴關係
    • 推出和增強新產品
    • 投融資
    • 獎賞,表彰,擴大

第11章企業可用性概況

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Carestream Health, Inc.
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Corporation
  • GE Healthcare Inc.
  • GlaxoSmithKline PLC
  • Hitachi, Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Philips Healthcare
  • S&P Global Inc.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Toshiba Corporation
  • Toshiba Medical Systems

第12章附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-CA17E905E62D

The Global Brain Tumor Diagnosis & Therapeutics Market size was estimated at USD 1,260.91 Million in 2020 and expected to reach USD 1,372.47 Million in 2021, at a Compound Annual Growth Rate (CAGR) 9.18% to reach USD 2,136.46 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Brain Tumor Diagnosis & Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Brain Tumor Diagnosis & Therapeutics Market was studied across Diagnosis and Therapeutics. The Diagnosis is further studied across Cerebral Arteriogram, CT Scan, EEG, Lumbar Puncture, Molecular Testing, MRI, PET-CT Scan, and Tissue Sampling. The Therapeutics is further studied across Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.

Based on Geography, the Brain Tumor Diagnosis & Therapeutics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Brain Tumor Diagnosis & Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Brain Tumor Diagnosis & Therapeutics Market, including Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co, Carestream Health, Inc., Eisai Inc., F. Hoffmann-La Roche Ltd, Fujifilm Corporation, GE Healthcare Inc., GlaxoSmithKline PLC, Hitachi, Ltd., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer, Inc., Philips Healthcare, S&P Global Inc., Shimadzu Corporation, Siemens Healthineers AG, Toshiba Corporation, and Toshiba Medical Systems.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Brain Tumor Diagnosis & Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Tumor Diagnosis & Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Brain Tumor Diagnosis & Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Brain Tumor Diagnosis & Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Brain Tumor Diagnosis & Therapeutics Market?
  • 6. What is the market share of the leading vendors in the Global Brain Tumor Diagnosis & Therapeutics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Brain Tumor Diagnosis & Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Type Outlook
  • 3.4. Geography Outlook
  • 3.5. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of neurological disorders
      • 5.1.1.2. Need for tests detecting the presence of tumors
      • 5.1.1.3. Research activities in the molecular diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the diagnosis and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising healthcare expenditure and the favorable reimbursement policies
      • 5.1.3.2. Growing healthcare awareness about the management and therapies of brain tumor
      • 5.1.3.3. Government initiatives for cancer awareness
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with brain tumor therapeutics
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Brain Tumor Diagnosis & Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnosis
    • 6.2.1. Cerebral Arteriogram
    • 6.2.2. CT Scan
    • 6.2.3. EEG
    • 6.2.4. Lumbar Puncture
    • 6.2.5. Molecular Testing
    • 6.2.6. MRI
    • 6.2.7. PET-CT Scan
    • 6.2.8. Tissue Sampling
  • 6.3. Therapeutics
    • 6.3.1. Chemotherapy
    • 6.3.2. Immunotherapy
    • 6.3.3. Radiation Therapy
    • 6.3.4. Surgery
    • 6.3.5. Targeted Therapy

7. Americas Brain Tumor Diagnosis & Therapeutics Market

  • 7.1. Introduction
  • 7.2. Argentina
  • 7.3. Brazil
  • 7.4. Canada
  • 7.5. Mexico
  • 7.6. United States
    • 7.6.1. California
    • 7.6.2. Florida
    • 7.6.3. Illinois
    • 7.6.4. New York
    • 7.6.5. Ohio
    • 7.6.6. Pennsylvania
    • 7.6.7. Texas

8. Asia-Pacific Brain Tumor Diagnosis & Therapeutics Market

  • 8.1. Introduction
  • 8.2. China
  • 8.3. India
  • 8.4. Indonesia
  • 8.5. Japan
  • 8.6. Malaysia
  • 8.7. Philippines
  • 8.8. South Korea
  • 8.9. Thailand

9. Europe, Middle East & Africa Brain Tumor Diagnosis & Therapeutics Market

  • 9.1. Introduction
  • 9.2. France
  • 9.3. Germany
  • 9.4. Italy
  • 9.5. Netherlands
  • 9.6. Qatar
  • 9.7. Russia
  • 9.8. Saudi Arabia
  • 9.9. South Africa
  • 9.10. Spain
  • 9.11. United Arab Emirates
  • 9.12. United Kingdom

10. Competitive Landscape

  • 10.1. FPNV Positioning Matrix
    • 10.1.1. Quadrants
    • 10.1.2. Business Strategy
    • 10.1.3. Product Satisfaction
  • 10.2. Market Ranking Analysis
  • 10.3. Market Share Analysis, By Quadrant
  • 10.4. Market Share Analysis, By Company
  • 10.5. Competitive Scenario
    • 10.5.1. Merger & Acquisition
    • 10.5.2. Agreement, Collaboration, & Partnership
    • 10.5.3. New Product Launch & Enhancement
    • 10.5.4. Investment & Funding
    • 10.5.5. Award, Recognition, & Expansion

11. Company Usability Profiles

  • 11.1. Amgen Inc.
  • 11.2. AstraZeneca PLC
  • 11.3. Bayer AG
  • 11.4. Bristol-Myers Squibb Co
  • 11.5. Carestream Health, Inc.
  • 11.6. Eisai Inc.
  • 11.7. F. Hoffmann-La Roche Ltd
  • 11.8. Fujifilm Corporation
  • 11.9. GE Healthcare Inc.
  • 11.10. GlaxoSmithKline PLC
  • 11.11. Hitachi, Ltd.
  • 11.12. Johnson & Johnson
  • 11.13. Merck & Co. Inc.
  • 11.14. Novartis AG
  • 11.15. Pfizer, Inc.
  • 11.16. Philips Healthcare
  • 11.17. S&P Global Inc.
  • 11.18. Shimadzu Corporation
  • 11.19. Siemens Healthineers AG
  • 11.20. Toshiba Corporation
  • 11.21. Toshiba Medical Systems

12. Appendix

  • 12.1. Discussion Guide
  • 12.2. License & Pricing
  • 12.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
  • FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 8. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2026
  • FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CEREBRAL ARTERIOGRAM, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CEREBRAL ARTERIOGRAM, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CT SCAN, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CT SCAN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY EEG, 2018-2026 (USD MILLION)
  • FIGURE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY EEG, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LUMBAR PUNCTURE, 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LUMBAR PUNCTURE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR TESTING, 2018-2026 (USD MILLION)
  • FIGURE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR TESTING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MRI, 2018-2026 (USD MILLION)
  • FIGURE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MRI, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PET-CT SCAN, 2018-2026 (USD MILLION)
  • FIGURE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PET-CT SCAN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE SAMPLING, 2018-2026 (USD MILLION)
  • FIGURE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE SAMPLING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD MILLION)
  • FIGURE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2026 (USD MILLION)
  • FIGURE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2026 (USD MILLION)
  • FIGURE 36. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2026 (USD MILLION)
  • FIGURE 38. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 39. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 40. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 41. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 42. ARGENTINA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. BRAZIL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. CANADA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. MEXICO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. UNITED STATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. CALIFORNIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. FLORIDA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. ILLINOIS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. NEW YORK BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. OHIO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. PENNSYLVANIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. TEXAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 55. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 57. CHINA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. INDIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. INDONESIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. JAPAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. MALAYSIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. PHILIPPINES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. SOUTH KOREA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. THAILAND BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 66. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 67. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 68. FRANCE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. GERMANY BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. ITALY BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. NETHERLANDS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. QATAR BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. RUSSIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 76. SPAIN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 77. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 78. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 79. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 80. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 81. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 82. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CEREBRAL ARTERIOGRAM, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CT SCAN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY EEG, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LUMBAR PUNCTURE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR TESTING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MRI, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PET-CT SCAN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE SAMPLING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. ARGENTINA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. BRAZIL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. CANADA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. MEXICO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. UNITED STATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. UNITED STATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. CALIFORNIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. FLORIDA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. ILLINOIS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. NEW YORK BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. OHIO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. PENNSYLVANIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. TEXAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. CHINA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. INDIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. INDONESIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. JAPAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. MALAYSIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. PHILIPPINES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. SOUTH KOREA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. THAILAND BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. FRANCE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. GERMANY BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. ITALY BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. NETHERLANDS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. QATAR BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. RUSSIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. SPAIN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: SCORES
  • TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 60. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: RANKING
  • TABLE 61. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 62. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 63. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 64. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 65. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 66. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 67. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 68. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: LICENSE & PRICING
  • TABLE 69. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: CONTACT DETAILS